Xofigo an Advanced Prostate Cancer Drug Approved By FDA

Tuesday, Dec. 3rd 2013 5:00 AM

The Food and Drug Administration (FDA) approved Xifogo under the priority review program, three months ahead of schedule.   According to an online FDA communiqué published this week, Xofigo is aimed at male patients whose prostate cancer metastasized despite receiving medical or surgical interventions to reduce testosterone levels.

Posted on Tuesday, Dec. 3rd 2013 5:00 AM | by Share of Cost | in Share of Cost | Comments Off on Xofigo an Advanced Prostate Cancer Drug Approved By FDA